Impact

Our impact Principles

Informed impact

Understanding the bigger systems that determine progress in longevity, ensures that we identify efforts that make a real difference.

Leveraged impact

For the projects we take on, we strive to minimize administrative spend; which focuses both resources and incentives towards impact on our mission.

Efficient impact

We seek opportunities for outsized impact, by targeting critical areas where our actions can trigger additional effort or investment. Either by demonstrating feasibility or removing disincentives.

Proactive transparency improves incentives, and therefore impact. We share the outcomes of all our efforts, successes and missteps.

Accountable impact

At Norn, impact means enabling progress that wouldn’t happen otherwise.


We support early-stage science and the people behind it — helping ideas, labs, and careers take root in longevity research.

Since launching Impetus Grants, our funding has contributed to over 200 peer-reviewed publications and helped more than two dozen labs enter the longevity field and continue to make progress in it.

Our Longevity Apprenticeship program invested in people as much as ideas.
Alumni have gone on to found companies (see below), together raising more than 100× the cost of the program.

General Control

Founded by Longevity Apprenticeship alumna Lada Nuzhna, who also served as Director of Impetus Grants.

Becoming

Founded by Longevity Apprenticeship alumna Divya Dhar Cohen.

Beyond funding, we build shared momentum — convening the field through symposia and roundtables on challenges such as biomarkers.

Hear testimonials straight from those who joined us in building the momentum, and learn more about our specific programs and their impact below.

“Impetus funding allowed us to pursue a high-risk, high-reward idea at a critical moment, before traditional funders like NIH would have supported it. That early support directly enabled the development of our aging biomarker platform, now used in both clinical and research settings.”

Raghav Sehgal

Researcher, Yale University

“Impetus has consistently funded our novel biomolecular tools at conceptualization/fledgling stages, too preliminary for even the ‘exploratory’ NIH grants to support.”

Xiaojing Gao

Professor, Stanford University

“Impetus’ support enabled my lab to launch a brand-new research program exploring just how far we can extend lifespan in C. elegans. I love how the straightforward, concise application is so well suited for projects that pioneer new directions.”

Javier Apfeld

Professor, Northeastern University

“Me and my colleague were only junior postdocs when we received the grant. It allowed us to transition full time into longevity research (instead of it being a side-activity), making preclinical and clinical trials of geroprotective compounds our sole research focus. I think it is fair to say, without exaggeration, that the Impetus funds lay the foundation for our lab and its entire research agenda today.”

Pontus Plavén-Sigray

ERAP trial group - Karolinska Institutet

“The Impetus grant made a real difference. While aging research is the main focus of our lab, the grant encouraged us to rethink our approaches and pursue high-risk, high-reward ideas that traditional funders would not support. What I truly appreciate is that Impetus is willing to back innovative ideas, even without extensive preliminary data–something that’s often required by other agencies, yet hard to generate without funding in the first place.
Another important aspect is that Impetus supports projects based on the strength of the idea, regardless of whether the applicant is a PI or a trainee. This made a significant difference to a PhD student in my lab, whose career and motivation were meaningfully boosted by this opportunity.”

Dr. David Vilchez

Professor, CECAD Research Center - University of Cologne

“The Impetus grant played a key role in advancing my research. It provided essential support for generating preliminary data that laid the groundwork for future successful grant applications. It thus enabled us to launch a new line of research in my lab. The entire process—from application to funding—was seamless, allowing us to start the project without delay.”

Eliisa Kekäläinen

Professor, University of Helsinki

“As a new Principal Investigator, the funding we received from Impetus has really been game changing. The fast turnaround on review time allowed me to quickly expand my brand-new research team. The ‘bold ideas’ approach funded by Impetus allowed us to be more daring than we can afford to be in traditional grants. Perhaps most importantly, the value Impetus places on projects and ideas - rather than CVs and seniority - allowed me to have access to an unparalleled opportunity as a new PI. This grant, as its name promises, has truly been an ‘impetus’ for my new research group. I am very grateful for the opportunity and support, and looking forward to the results we will obtain.”

Marta Kovatcheva

Researcher, Laboratory of Cell Plasticity & Aging, IFOM

“The grant for me was a perfect opportunity for two (connected) reasons: 1. Australian funding schemes do not recognise ageing research as a field in the same way that most of the rest of the world do, so it was extremely important for my research program to get Impetus funding 2. We had an idea based on preliminary data that pointed to a new longevity intervention. An idea at the stage of research we were at would not have been funded through conventional channels. It turned out that our hypothesis was correct and so from a fairly preliminary starting position, we accelerated from idea to realization because of Impetus money. This story was published in the dedicated special issue of Geroscience last year and has already been accessed ~7000 times and cited 11 times.”

Matthew Piper

Professor, Monash University

“Starting my lab with limited funds, Impetus gave me the freedom to take risks and explore new ideas outside my comfort zone. It helped me grow my skills, attract additional funding, and broaden my perspective, leading to exciting collaborations and fresh research directions.”

Federico Pietrocola

Researcher, Cellular Stress in Health and Disease Lab - Karolinska Institutet

“Although redox imbalance is implicated in all hallmarks of aging, our lab recognizes that its underlying causes remain understudied in the aging field. The funding we received from Impetus Grants was instrumental in supporting our development of reagents to directly test how modulation of cellular redox state - linked to redox coenzymes NAD and NADP - can be harnessed to better understand its role on health- and lifespan. We pursued this work in Drosophila as part of a collaboration with the Parkhitko lab at the University of Pittsburgh.
To this day, I remember the joy of receiving the Impetus Grant after unsuccessfully trying to secure funding from AFAR for the same exact project. The generous support allowed us to directly test how modulation of redox state using genetically encoded tools or small molecule redox-cyclers (alone or in combination with known ‘NAD boosters’) promotes stress-resistance and sex-dependent changes in health- and lifespan.
We are confident that in the coming years, our lab will demonstrate multiple examples showing that “fixing” redox imbalance is a more effective strategy to attack aging compared to just “boosting total NAD levels”, which can even be harmful in certain circumstances. These insights would have not been possible without funding from Impetus Grants.”

Valentin Cracan

Professor, Scintillon Research Institute

“When our secretome project was still too risky for traditional funding, Impetus Grants stood out as a uniquely fast and significant funding opportunity. Impetus’ support specifically enabled us to hire a dedicated technician and more quickly achieve proof-of-concept for a new research method.”

Josh Tycko

Post-Doc, Harvard Medical School & BIDMC

“We are an early stage lab proposing an ambitious idea: to learn how torpor and hibernation affect aging. We had no funding for this research and the Impetus grant allowed us to begin pursuing these questions.”

Sinisa Hrvatin

Professor, MIT & Whitehead Institute

“Impetus funding provided key bridge support for maintaining our Spiny Mice (Acomys) colony, a non-traditional experimentally tractable mammalian regenerative model system meeting new and changing NIH policies. Impetus encouraged us to pursue a topic deemed too complex via traditional routes. Without Impetus support, we would not have successfully discovered new beneficial aging linked neuroimmune healthspan adaptations in Acomys that could be used to relandscape human aging outcomes for increased healthspans. Impetus provided our breakthrough and hopefully can continue to incentivize this type of research, pioneering novel funding mechanisms to uncover naturally selected biological solutions for promoting human health and longevity.”

Branden Nelson

Researcher, Seattle Children’s Research Institute

“Impetus is the best grant program for aging. It found and funded the right people to shift them to aging. I see Impetus all over the place in interesting work, almost never see Hevolution even though they have more money.”

Sophia Liu

Researcher, Ragon Institute of Mass General, MIT, and Harvard

Lauren Nam - Nexus

Testimonials

Become a Patron of Longevity Progress:

ANCHOR A PROGRAM

We have mapped the levers of progress in the longevity field. Based on this understanding, we identify maximum-leverage opportunities to address the biggest bottlenecks and advance progress.

Explore our shovel-ready programs below. If you are interested in becoming the anchor patron for a specific thesis, please reach out to our team.

Likewise, if you have an idea to anchor, reach out.

FERTILIZE THE FIELD

We understand bottlenecks from continuously mapping and engaging with challenges in longevity. As we do this we produce public goods, from analyses to explainers, that allow the field to thrive.

This mandate is not directly funded, but we’ll continue doing so as long as Norn operates. Your support ensures that continuity and growth.

Contribute to Norn

Future Programs:

Past Programs & Outcomes

Longevity Apprenticeship (2021)

Date

2021

Funding amount

$100 K

The Longevity Apprenticeship paired early-career researchers with expert mentors to develop hands-on skills in longevity research operations, including grant management, lab techniques, and program leadership. Participants attended intensive workshops, collaborated on real-world projects, and received stipends to support their contributions.

For the primary goal of preparing new operators to contribute in longevity:
  • One graduate student became Impetus Grant director and later launched a longevity biotech startup (seed stage).
  • One professional launched a biotech company (seed stage).
  • One recent grad is now Chief of Staff at a longevity startup.
  • One undergrad is pursuing an industry PhD in longevity & ML.
  • One undergrad launched a health startup (pre-seed stage).

Additional Outcomes:

  • Enabled launch of Impetus Grants.
  • Produced “Major Papers in Aging” curriculum now used by Longevity Biotech Fellowship

  • Produced Overview of age-related diseases as a resource for longevity startups

  • When ARPA-H launched, ran an unofficial recruiting campaign: contacted ~100 candidates, spoke with 47, arranged calls for 11, and provided advice from former DARPA PMs. Two joined ARPA-H as PMs, launching PROSPR and FRONT.

Operational spend

<0.1 %

Donor(s)

Astera Institute, The Michael Antonov Foundation

Nexus (2024 - Ongoing)

Date

2024 - Ongoing

Funding amount

$0

Nexus our research oriented "do-tank" brings people together to connect with mission‑oriented peers, organize and lead weekly journal clubs, and conduct deep dives into biology, biotechnology, and drug development, producing both internal knowledge‑base write‑ups and high‑quality public resources to advance the longevity field.
Participants may receive fellowships and mentorship to pursue meaningful projects within Norn Group.

Outcomes:

Operational spend

---

Donor(s)

---

Impetus Grants | Rounds 1, 2, 3 (2021 - 2023)

Rounds 1 & 2

Date

2021

Funding amount

≈ $25 M

Round 3

Date

2023

Funding amount

$10 M


Impetus Grants is Norn Group’s rapid‑response fund for high‑risk, high‑reward aging research, offering academic and non‑profit scientists up to $500 K within three weeks to tackle the field’s most critical challenges.
Since its launch, Impetus has deployed over $34 M across 146 pioneering projects. In Round 3, 34 teams were selected from more than 1,000 applications, accelerating breakthroughs that traditional grants often overlook.

Outcomes:

Primary metric:Conference sessions on topics not studied before Impetus funding (data forthcoming).

Leading metrics:

  • >200 papers/dissertations citing support from Impetus Grants.
  • Highlights include a new aging modulation method, record worm-lifespan extension, novel tools & animal models, and rapamycin clinical trials.
  • 40+ labs with no prior aging research launched projects; several continue post-Impetus.
  • Two companies spun out related to funded work.


Operational spend

1.1 %


Donor(s)

Hevolution Foundation, Rosenkranz Foundation, Juan Benet, Michael Antonov, Vitalik Buterin, James Fickel, Jed McCaleb, Karl Pfleger, Fred Ehrsam, Molly Mackinlay, Feruell, Gitcoin

Donor(s)

Rosenkranz Foundation, Hevolution Foundation


Talent Bridge [V2] (2025 - Ongoing)

Date

2025

Funding amount

$250 K

After reworking the program Talent Bridge has become an award & project-based program.
Talent Bridge identifies and supports exceptional global researchers dedicated to advancing aging science by providing comprehensive project funding, personalized mentorship, and seamless integration into Norn's network.
Participants are selected through competitive proposal submissions and receive targeted support with funding, and relocation to collaborate on high‑impact longevity research projects within Norn Group’s network The program

Outcomes:
  • The program remains focused on bringing talent to the US, with a new financial model.
  • We expect to help 20+ individuals reach the US to work on longevity using remaining funds, twice the original goal at less than half the original funding target.
  • Awardee list can be found here.

Operational spend

$0

Donor(s)

Schmidt Futures, James Fickel, Karl Pfleger, Sonia Arrison

Talent Bridge [V1] (2021)

Date

2021

Funding amount

$425 K

Talent Bridge (legacy) recruited and relocated exceptional bench, computational, and transitioning researchers worldwide—allocating 80 percent of their time to high‑impact aging biology projects at partner biotech companies and academic labs, and 20 percent to co‑designing training, mentorship, and career pathways for emerging talent.
Supported by volunteers who scout candidates, review CVs, and build open‑source resources, the program streamlines entry into aging research and accelerates therapeutic innovation.

Outcomes:
  • The original goals were to bring 5-10 talented individuals to the US, and to prove out a visa model and share with 2+ other organizations.
  • Initially the program had a $1M raise target dedicating 80+% going to recipients.
  • The financial model of the first program version did not work and was replaced in the second version of the program.
  • The visa model remains feasible, and has been shared with multiple research non-profits.

Operational spend

<$100 K

Donor(s)

Schmidt Futures, Emergent Ventures, James Fickel, Karl Pfleger, Sonia Arrison